Member Info for AquaeSulis01

Bournemouth Tom "Sorry the free thinking and lefty journalists at C4 are what the government wants gone."

Odd that Tony Blair should have considered the smae privatisation action then

"With ministers plotting to privatise Channel 4, the broadcaster’s chairman sat down and decided to pen a heartfelt letter to his friend, the Prime Minister.

Pushing ahead with a sale would trigger a political firestorm and threaten the channel’s distinctive output, Sir Michael Bishop warned, opening his appeal with a personal “Dear John…”.

The letter was sent in 1996, not 2022, yet it shows how Channel 4’s future - revisited under Tony Blair and David Cameron as well - has been debated regularly since its inception, often with similar arguments. "

Yes I know Phat and let's hope there are no more banana skins. I guess the point I was trying to draw out is that if you pay top dollar for a company the size of skin for an experienced CEO, there shouldn't really be too many "steep learning curves". It would also help if Stuart bought a few more shares at market price as other AIM CEO's such as Cathal Freal (Open Orphan) and Paul Johnson (Power Metal Resources) have done

clio "We just have to hope we’ve recruited people with initiative, which to be frank will be a challenge at the salaries offered."
Talking of salaries, I must admit that when Stuart talked about taking quite a haircut in terms of salary when he joined Skin, I assumed he was being paid a very moderate salary. Now I don't know what the average CEO salary is for an early commercial stage growth company on aim but must admit to being shocked to see he gets paid more than the CEO of Ceres Power so only right he answers searching questions when missing targets.
Share based Pension Total
"Executive Salaries Fees payments contributions remuneration
Stuart Ashman £323,296 – £43,899 £5,523 £372,718 "
https://www.skinbiotherapeutics.com/wp-content/uploads/2021/11/SBTX-Annual-Report-Accounts-June-21.pdf

Stop him not dolphin

It didn't dolphin ordering £400k of inventory upfront though without the staff to shift it. Why order so much and make a big deal about being Winclove's second biggest customer unless he thought he could shift it quickly with the resources he had?

They are not waiting for the next pandemic, planning for it and R&D for vaccines, which will require testing, is underway.
https://www.telegraph.co.uk/global-health/science-and-disease/zika-dengue-among-viruses-could-spark-next-pandemic/
"Zika and dengue among viruses that could spark the ‘next pandemic’
Experts are scrambling to develop strategies to stop next outbreak escalating into a catastrophe. Targeting arboviruses is top of the list
“We have been through two years of Covid-19 pandemic and we have learned the hard way what [it costs] not to be prepared for high impact events,” Dr Sylvie Briand, director of the global infectious hazard preparedness team at the WHO, said on Thursday.
Researchers in countries from Brazil to Senegal have been working on arboviruses for decades, but this is the first time a global strategy has been presented. It includes plans to improve disease surveillance, putting early warning systems in place and developing new treatments, vaccines and diagnostics."

Toyin, personally I hope your optimism re take up is right because when I raised the question re "leasing" the 10000 sq m warehouse and was told by Stuart at the Investor Meets event that the RNS didn't say that and they only pay for the space they need (RNS stated "Through its subsidiary AxisBiotix Limited ("AxisBiotix"), SkinBioTherapeutics has begun receiving and storing finished product at its distribution centre in the Netherlands. The warehouse is 10,000sq metres and is located in Boxtel near Eindhoven which has been carefully chosen for its proximity to the Company's formulation partner, Winclove and its distribution links to the US, UK and Europe. Readying of finished product is ahead of schedule for launch") so make your own minds up how that should be interpreted, I would just caution that with an upfront purchase of over £400K of inventory, that is enough for 40,000 boxes of axis and will take up warehouse space until it is sold.

Yes, I will certainly start to get concerned if we start getting big buys from Albanian Investors. On a more serious note, the low base skin starts from as opposed to the optimistic figures quoted during some of the pre-launch podcasts are due not only to the soft launch but also to the error made in the USA NPF membership numbers assumption and hence the influence the "partner" could have post launch. Membership numbers of 7-8 million were spoken of which represents the estimated number of US psoriasis sufferers who of course are not all members, whilst the true demographics of US NPF email members are:
409,808 U.S. mailing addresses
61 percent female; 39 percent male
46 percent diagnosed with psoriasis
29 percent diagnosed with psoriatic arthritis
25 percent caregiver for someone with psoriasis and/or psoriatic arthritis
Average age is 49; 54 percent are 35-60 years old.

Now 409,803 members are not an insubstantial figure ,so if the USA NPF ever does get fully onboard with promoting Axisbiotix it will certainly help accelerate sales, but as things stand we must just hope that B2C sales pick up a lot faster than Opti B2B ingredient sales , which I am sure with their targeted influencer market spend they will.

Thanks for the link Trojan. Interesting comment from SOH re companies interested in acquiring the probiotic part of the company for circa £25M and certainly helps underpin the current share price as it will be far easier to place an offer now it is separated out; current major customers for LPLDL must be high up on that list of suitors

thanks

Thams mol

Yes I did Farris, just need to get sweetbiotix launched so that Opti prebiotic revenue matches the revenue of the Chinese company purchased at that value

What is noticeable is that demand for the new shares has been strong as evidenced by th elower than announced Optibiotix Health holding which we were told would be between 46-48% when the listing was announced whilst today's announcement states the holding is 44%
"The Dividend Shares are expected to represent between 35% and 37% of the issued share capital of ProBiotix Health admitted to trading on the AQSE Growth market. Following the Distribution, the Company will hold between 46-48%, with the remaining 13- 18% held by new shareholders."
"
Following the distribution in specie of Ordinary Shares to its shareholders, OptiBiotix remains interested in 53,533,333 Ordinary Shares, representing approximately 44% of the issued share capital of ProBiotix Health plc."

https://www.youtube.com/watch?v=llmMJakRRW4

More importantly it doesn't include any revenue forecasts for the three big contracts announced recently for the new commercial contracts with ; The Hut Group, Apollo Hospitals (India) and Nahdi Medical (KSA) which apparently are going well

bitcoin, with a junior mining exploration company, until you see the magic words "we have a commercial discovery or better still a district scale discovery, on our hands it will remain a binary play, all or nothing, so having the opportunity to do a partial sale and bank the profits to offset any risk of losing the lot makes perfect sense

TW is not worried because he has it in a SIPP for long term investment and payback, he also purchases skin shares on a monthly basis and started when they were around 15p so when they are cheaper he gets more for his money that month. He is also more pragmatic and believes that the seven figure revenue sum will be hit by Christmas and not overnight. SA, probably on the back of the enthusiasm shown by the USA NPF no doubt thought more sales would flow from passive word of mouth than has been the case. A lesson learnt and the limited, but targeted marketing will steadily increase sales

Agreed Phat

Mad, the retention levels are excellent and long term this company will be a great investment
Phat it will not be a marginal miss hence the wording , "The Company expects its revenue for the full year to be materially below market expectations." Materially does not = marginal

Yes should be there by the end of the year